Aurobindo-Sandoz End $1bn US Deal
Trade Clearance Not Forthcoming
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
You may also be interested in...
Most roads led to India in 2020 when it came to deals to expand access to COVID-19 therapies, but the challenging year also saw significant private equity interest and there are expectations of more action ahead in the new year.
The two RNAi firms cross-license IP from their PH programs, while also partnering on a rare liver disease candidate. GSK invests $250m in Vir and will help to advance its antibody candidates for COVID-19.
The termination of the Aurobindo-Sandoz deal isn’t perhaps all bad news for the Indian firm and the flip side may be an improved balance sheet, according to some analysts. But the resolution of compliance issues at manufacturing facilities remains critical.